INT10059

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1990
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 17
Disease Relevance 5.28
Pain Relevance 3.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CSH1) extracellular region (CSH1)
Anatomy Link Frequency
blood 1
spinal 1
hepatocytes 1
muscle 1
CSH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
anesthesia 30 100.00 Very High Very High Very High
corticosteroid 296 99.80 Very High Very High Very High
backache 1 96.56 Very High Very High Very High
epidural 1 94.72 High High
carbamazepine 11 94.44 High High
anticonvulsant 8 93.84 High High
Inflammation 135 86.92 High High
local anesthetic 2 85.24 High High
intrathecal 2 84.56 Quite High
headache 16 82.32 Quite High
Disease Link Frequency Relevance Heat
Hirsutism 8 99.90 Very High Very High Very High
Diabetes Mellitus 61 99.64 Very High Very High Very High
Gingival Hyperplasia 8 99.62 Very High Very High Very High
Systemic Lupus Erythematosus 14 99.02 Very High Very High Very High
Atherosclerosis 17 98.40 Very High Very High Very High
Infection 35 97.44 Very High Very High Very High
Death 56 97.00 Very High Very High Very High
Renal Failure 88 96.76 Very High Very High Very High
Renal Disease 64 96.72 Very High Very High Very High
Back Pain 1 96.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We therefore anticipated that any drug that is an inducer or an inhibitor of this cytochrome should lead to interaction with CsA when given in association with it.
CsA Binding (interaction) of
1) Confidence 0.35 Published 1990 Journal Drug Metab. Dispos. Section Abstract Doc Link 1981707 Disease Relevance 0 Pain Relevance 0
This review compares CSA with other anesthetic techniques and also describes the history of CSA, its clinical applications, concerns regarding neurotoxicity, and other pharmacologic implications of its use.
CSA Binding (compares) of associated with anesthesia and drug induced neurotoxicity
2) Confidence 0.31 Published 2009 Journal Am J Ther Section Abstract Doc Link 19546804 Disease Relevance 0.26 Pain Relevance 1.41
Complications of CSA are categorized as general, the same as those associated with single-shot spinal anesthesia, and specific, those associated solely with CSA.
CSA Binding (associated) of in spinal associated with anesthesia
3) Confidence 0.30 Published 1992 Journal CRNA Section Abstract Doc Link 1458249 Disease Relevance 0.60 Pain Relevance 1.03
Our results allowed us to elucidate the molecular mechanism of previously observed, but unexplained, drug interactions involving CsA, and to detect drugs that should interfere with CsA metabolism as inducers or inhibitors.
CsA Binding (interactions) of
4) Confidence 0.27 Published 1990 Journal Drug Metab. Dispos. Section Abstract Doc Link 1981707 Disease Relevance 0 Pain Relevance 0.14
In order to confirm this hypothesis, primary cultures of human hepatocytes and human liver microsomes were used to "reproduce" in vitro clinically significant interactions observed between CsA and drugs known either as specific inducers (i.e., rifampicin) or as specific inhibitors (i.e., erythromycin) of P-450IIIA.
CsA Binding (interactions) of in hepatocytes
5) Confidence 0.23 Published 1990 Journal Drug Metab. Dispos. Section Abstract Doc Link 1981707 Disease Relevance 0 Pain Relevance 0
Participants were exposed to one of the four following experimental conditions related to expert testimony: accusing daughter and accused father's testimonies regarding alleged CSA plus (1) two expert testimonies, one each for the daughter and the father; (2) an expert testimony for the daughter; (3) an expert testimony for the father; or (4) no expert testimony.
CSA Binding (regarding) of
6) Confidence 0.13 Published 2002 Journal BMC Med Ethics Section Body Doc Link PMC111059 Disease Relevance 0.07 Pain Relevance 0
Interferon tau activates the JAK-STAT pathway within the cells, while binding of placental lactogen promotes formation of STAT5 homodimers.
placental lactogen Binding (binding) of
7) Confidence 0.13 Published 2007 Journal Placenta Section Body Doc Link PMC1878510 Disease Relevance 0.15 Pain Relevance 0
There have been reports of a serious drug interaction between Csa and the herbal dietary supplement, Saint.
Csa Binding (interaction) of
8) Confidence 0.07 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0 Pain Relevance 0.12
Reduced thigh CSA was associated with poorer LEP, as was reduced thigh muscle attenuation coefficient, even after the adjustment for muscle area.
CSA Binding (associated) of in muscle
9) Confidence 0.06 Published 2009 Journal Osteoporos Int Section Body Doc Link PMC2832869 Disease Relevance 0.31 Pain Relevance 0
The interaction between rifabutin and Csa has not been well studied but care should be exercised when these two drugs are administered concomitantly.

5.6.

Csa Binding (interaction) of
10) Confidence 0.06 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0 Pain Relevance 0.08
mg and five milligrams, respectively, of sirolimus in combination with Csa and CS.
Csa Binding (combination) of associated with corticosteroid
11) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.24 Pain Relevance 0.09
Gingival hyperplasia and hirsutism are associated with Csa whereas diabetes is more common with tacrolimus.
Csa Binding (associated) of associated with hirsutism, diabetes mellitus and gingival hyperplasia
12) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.94 Pain Relevance 0.06
Csa and tacrolimus are calcineurin inhibitors that bind to their specific immunophilins, cyclophilin and FK binding protein, respectively, before the drug-receptor complex binds to and inhibits calcineurin, a calcium-dependent phosphatase.
Csa Binding (bind) of
13) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.07 Pain Relevance 0
Csa and tacrolimus are calcineurin inhibitors that bind to their specific immunophilins, cyclophilin and FK binding protein, respectively, before the drug-receptor complex binds to and inhibits calcineurin, a calcium-dependent phosphatase.
Csa Binding (binds) of
14) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.07 Pain Relevance 0.03
Early trials comparing basiliximab combined with Csa, AZA, and CS or used with Csa and steroids were associated with an ACR rate of 35% [112, 113].
Csa Binding (combined) of associated with corticosteroid
15) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.67 Pain Relevance 0.13
In plasma, approximately 90% is bound to proteins, primarily lipoproteins.Csa elimination in blood is biphasic with a half-life of approximately 18 hours (range: 10 to 27?
Csa Binding (bound) of in blood
16) Confidence 0.05 Published 2009 Journal Journal of Transplantation Section Body Doc Link PMC2809333 Disease Relevance 0.12 Pain Relevance 0.05
In SLE, although Farzaneh-Far et al. [42] suggest that aPL are not associated with increased preclinical or clinical atherosclerosis and arterial stiffening, these antibodies may be a cause of arterial damage which initiates atherogenesis [39].
aPL Binding (associated) of associated with atherosclerosis and systemic lupus erythematosus
17) Confidence 0.01 Published 2010 Journal The Open Cardiovascular Medicine Journal Section Body Doc Link PMC2847817 Disease Relevance 1.78 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox